Northwest Biotherapeutics (NWBO) 10-Q 21 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 21, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Entity Registrant Name	NORTHWEST BIOTHERAPEUTICS INC
Entity Central Index Key	1,072,379
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	NWBO
Entity Common Stock, Shares Outstanding		295,253,044

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 22	$ 6,186
Restricted cash - interest payments held in escrow	0	685
Prepaid expenses and other current assets	797	1,013
Total current assets	819	7,884
Non-current assets:
Property, plant and equipment, net	224	315
Construction in progress (property in the United Kingdom)	46,221	44,559
Other assets	119	148
Total non-current assets	46,564	45,022
Total assets	47,383	52,906
Current liabilities:
Accounts payable and accrued expenses	16,149	13,239
Accounts payable and accrued expenses to related parties	21,373	23,393
Convertible notes, net	3,495	10,960
Notes payable, net	5,661	2,450
Notes payable to related party	2,170	310
Share settled debt, at fair value (in default)	4,749	5,200
Environmental remediation liability	6,200	6,200
Warrant liability	6,878	4,862
Mortgage loan, net	6,115	9,791
Total current liabilities	72,790	76,405
Non-current liabilities:
Note payable, net of current portion, net	0	3,000
Convertible notes payable, net of current portion, net	5,383	0
Mortgage loan, net of current portion, net	4,453	0
Total non-current liabilities	9,836	3,000
Total liabilities	82,626	79,405
Commitments and Contingencies
Stockholders' equity (deficit):
Preferred stock ($0.001 par value); 40,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	0	0
Common stock ($0.001 par value); 450,000,000 shares authorized; 237,322,805 and 157,028,270 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	237	157
Additional paid-in capital	702,661	686,972
Accumulated deficit	(738,349)	(715,476)
Accumulated other comprehensive gain	208	1,848
Total stockholders' equity (deficit)	(35,243)	(26,499)
Total liabilities and stockholders' equity (deficit)	$ 47,383	$ 52,906

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	40,000,000	40,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	450,000,000	450,000,000
Common stock, shares issued	237,322,805	157,028,270
Common stock, shares outstanding	237,322,805	157,028,270

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues:
Research and other	$ 88	$ 157	$ 156	$ 393
Total revenues	88	157	156	393
Operating costs and expenses:
Research and development	5,466	8,713	10,501	22,153
General and administrative	3,284	1,926	6,289	5,261
Legal expenses	2,003	4,541	5,935	5,481
Total operating costs and expenses	10,753	15,180	22,725	32,895
Loss from operations	(10,665)	(15,023)	(22,569)	(32,502)
Other income (expense):
Change in fair value of derivative liabilities	6,457	3,930	7,896	17,455
Loss from extinguishment of debt	(7,007)	0	(8,542)	0
Interest expense	(1,308)	(729)	(2,502)	(1,447)
Foreign currency transaction gain (loss)	2,270	(2,353)	2,844	(3,787)
Net loss	(10,253)	(14,175)	(22,873)	(20,281)
Deemed dividend related to warrant modification	0	(2,640)	0	(2,640)
Net loss applicable to common stockholders	$ (10,253)	$ (16,815)	$ (22,873)	$ (22,921)
Net loss per share applicable to common stockholders - basic and diluted (in dollars per share)	$ (0.05)	$ (0.16)	$ (0.12)	$ (0.23)
Weighted average shares used in computing basic and diluted loss per share (in shares)	208,458	103,831	185,108	100,782

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net loss	$ (10,253)	$ (14,175)	$ (22,873)	$ (20,281)
Other comprehensive loss
Foreign currency translation adjustment	(1,326)	537	(1,640)	1,037
Total comprehensive loss	$ (11,579)	$ (13,638)	$ (24,513)	$ (19,244)

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT) - 6 months ended Jun. 30, 2017 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Cumulative Translation Adjustment [Member]
Balance at Dec. 31, 2016	$ (26,499)	$ 157	$ 686,972	$ (715,476)	$ 1,848
Balance (in shares) at Dec. 31, 2016		157,027
Issuance of common stock and warrants for cash in a registered direct offering (net of $6.4 million warrant liability)	1,389	$ 20	1,369	0	0
Issuance of common stock and warrants for cash in a registered direct offering (net of $6.4 million warrant liability) (in shares)		20,229
Offering cost related to registered direct offering	(693)	$ 0	(693)	0	0
Issuance of common stock and warrants for cash in private offering (net of $0.3 million warrant liability)	232	$ 4	228	0	0
Issuance of common stock and warrants for cash in private offering (net of $0.3 million warrant liability) (in Shares)		3,611
Warrants exercised for cash	100	$ 10	90	0	0
Warrants exercised for cash (in shares)		10,000
Reclassification of warrant liabilities related to warrants exercised for cash	1,847	$ 0	1,847	0	0
Conversion of share settled debt into common stock	451	$ 3	448	0	0
Conversion of share settled debt into common stock (in shares)		3,500
Issuance of common stock and warrants for conversion of debt and accrued interest	6,266	$ 36	6,230	0	0
Issuance of common stock and warrants for conversion of debt and accrued interest (in Shares)		35,866
Common stock issued for extinguishment of 2014 senior convertible notes	2,054	$ 7	2,047	0	0
Common stock issued for extinguishment of 2014 senior convertible notes (in shares)		7,090
Forgiveness of certain payables to Cognate BioServices, Inc.	3,750	$ 0	3,750	0	0
Stock-based compensation	373	0	373	0	0
Net loss	(22,873)	0	0	(22,873)	0
Cumulative translation adjustment	(1,640)	0	0	0	(1,640)
Balance at Jun. 30, 2017	$ (35,243)	$ 237	$ 702,661	$ (738,349)	$ 208
Balance (in shares) at Jun. 30, 2017		237,323

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT) [Parenthetical] $ in Thousands	Jun. 30, 2017USD ($)
Derivative Liability, Current	$ 6,878
Direct Offering [Member]
Derivative Liability, Current	6,400
Private Offering [Member]
Derivative Liability, Current	$ 300

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash Flows from Operating Activities:
Net Loss	$ (22,873)	$ (20,281)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization	100	80
Amortization of debt discount	687	431
Non-cash interest expense	348	0
Change in fair value of derivatives	(7,896)	(17,455)
Loss from extinguishment of debt	8,542	0
Stock-based compensation	373	12
Stock issued to Cognate BioServices under Cognate Agreements	0	2,277
Subtotal of non-cash charges	1,704	(14,655)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	212	337
Accounts payable and accrued expenses	3,222	628
Related party accounts payable and accrued expenses	1,730	2,121
Other non-current assets	29	49
Net cash used in operating activities	(15,976)	(31,801)
Cash Flows from Investing Activities:
Purchase of property, plant and equipment	(9)	(4,303)
Refund of leasehold improvement related to UK construction	220	0
Net cash provided by (used in) investing activities	211	(4,303)
Cash Flows from Financing Activities:
Proceeds from issuance of common stock and warrants in a registered direct offering	7,760	10,000
Offering cost related to registered direct offering	(693)	(756)
Proceeds from issuance of common stock and warrants in private offering	553	0
Proceeds from exercise of warrants	100	4,235
Offering cost related to warrants exercise	0	(341)
Proceeds from issuance of notes payable, net	3,973	0
Proceeds from issuance of notes payable to related party	2,740	0
Repayment of notes payable to related parties	(880)	0
Proceeds from issuance of convertible notes payable, net	1,604	0
Repayment of convertible notes payable	(3,258)	0
Net cash provided by financing activities	11,899	13,138
Effect of exchange rate changes on cash and cash equivalents	(2,983)	3,021
Net decrease in cash, cash equivalents and restricted cash	(6,849)	(19,945)
Cash, cash equivalents and restricted cash, beginning of the period	6,871	23,048
Cash, cash equivalents and restricted cash, end of the period	22	3,103
Supplemental schedule of non-cash investing and financing activities:
Conversion of share settled debt into common stock	451	0
Issuance of common stock and warrants for conversion of debt and accrued interest	5,462	0
Exchange 2014 Senior Convertible Notes and accrued interest for secured convertible note	5,175	0
Reclassification of warrant liabilities related to warrants exercised for cash	1,847	0
Issuance of warrants in conjunction with note payable	83	0
Forgiveness of certain payables to Cognate BioServices, Inc.	3,750	0
Embedded conversion features with issuance of secured convertible notes	1,826	0
Accrued renewal fee incurred from mortgage loan	0	301
Deemed dividend related to modification of warrant	0	2,640
VAT receivables related to UK property	0	408
Mortgage Loan [Member]
Supplemental disclosure of cash flow information
Interest payments	(658)	(920)
Convertible Notes Payable [Member]
Supplemental disclosure of cash flow information
Interest payments	(485)	(275)
Notes Payable, Other Payables [Member]
Reconciliation of net loss to net cash used in operating activities:
Amortization of debt discount	270	0
Supplemental disclosure of cash flow information
Interest payments	$ (47)	$ 0

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Description of Business Northwest Biotherapeutics, Inc. and its wholly owned subsidiaries NW Bio Gmbh, and Aracaris Capital, Ltd (collectively, the “Company”, “we”, “us” and “our”) were organized to discover and develop innovative immunotherapies for cancer. The Company is developing an experimental dendritic cell vaccine using its platform technology known as DCVax. DCVax is currently being tested for use in the treatment of certain types of cancers. Cognate BioServices, Inc. (“Cognate BioServices”), which is a company related by common ownership (Note 9), provides the Company with mission critical contract manufacturing services, research and development services, distribution and logistics, and related services, in compliance with the Company’s specifications and the applicable regulatory requirements for clinical grade cellular products. The Company and Cognate BioServices are currently parties to a series of contracts providing for these services as more fully described below. The Company is dependent on Cognate BioServices to provide the manufacturing services, and any interruption of such services could potentially have a material adverse effect on the Company’s ability to proceed with its clinical trials. Cognate BioServices’ manufacturing facility for clinical-grade cellular products is located in Memphis, Tennessee. In addition, a Cognate affiliate in the UK (which was formerly part of Cognate BioServices) is preparing for production of DCVax-L products there. Although there are many contract manufacturers for small molecule drugs and for biologics, there are only a few contract manufacturers in the U.S., and even fewer in Europe, that specialize in producing living cell products and that have a track record of success with regulatory authorities. The manufacturing of living cell products is highly specialized and entirely different than production of biologics: the physical facilities and equipment are different, the types of personnel and skill sets are different, and the processes are different. The regulatory requirements relating to manufacturing and cellular products are especially challenging and are one of the most frequent reasons for the development of a company’s cellular products to be put on clinical hold (i.e., stopped by regulatory authorities). In addition, the Company’s programs require a large amount of capacity in these specialized manufacturing facilities. The Company’s products are fully personalized and not made in standardized batches: the Company’s products are made on demand, patient by patient, on an as needed basis.

Liquidity, Financial Condition

Liquidity, Financial Condition and Management Plans	6 Months Ended
	Jun. 30, 2017
Liquidity [Abstract]
Liquidity and Financial Condition [Text Block]	2. Liquidity, Financial Condition and Management Plans During the six months ended June 30, 2017 and 2016, the Company used approximately $ 16.0 31.8 During the six months ended June 30, 2017, the 16.0 5 from a third party who retired the 2014 Notes on the Company’s behalf (see Note 7 for further details) 10.3 22.9 0.8 72.0 21.4 3.75 The Company has not yet generated any material revenue from the sale of its products and is subject to all of the risks and uncertainties that are typically faced by biotechnology companies that devote substantially all of their efforts to R&D and clinical trials and do not yet have commercial products. The Company expects to continue incurring losses for the foreseeable future. The Company’s existing liquidity is not sufficient to fund its operations, anticipated capital expenditures, working capital and other financing requirements until the Company reaches significant revenues. Until that time, the Company will need to obtain additional equity and/or debt financing, especially if the Company experiences downturns in its business that are more severe or longer than anticipated, or if the Company experiences significant increases in expense levels resulting from being a publicly-traded company or from expansion of operations. If the Company attempts to obtain additional equity or debt financing, the Company cannot assume that such financing will be available to the Company on favorable terms, or at all. Because of recurring operating losses, net operating cash flow deficits, and an accumulated deficit, there is substantial doubt about the Company’s ability to continue as a going concern. The Company has operated with going concern determinations throughout more than a decade, and so the condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company did not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. Summary of Significant Accounting Policies The accompanying unaudited condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated. Certain immaterial reclassifications have been made to prior period amounts to conform to the current period presentation. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of June 30, 2017, condensed consolidated statements of operations for the three and six months ended June 30, 2017 and 2016, condensed consolidated statements of comprehensive loss for the six months ended June 30, 2017 and 2016, condensed consolidated statement of stockholders’ equity (deficit) for the six months ended June 30, 2017, and the condensed consolidated statements of cash flows for the six months ended June 30, 2017 and 2016 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and six months ended June 30, 2017 are not necessarily indicative of results to be expected for the year ending December 31, 2017 or for any future interim period. The condensed consolidated balance sheet at December 31, 2016 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2016, and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on April 17, 2017. In preparing condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, valuing environmental liabilities, estimating the fair value of financial instruments recorded as derivative liabilities, and estimating the useful lives of depreciable assets and whether impairment charges may apply. The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company's statements of operations. The fair value of the warrants issued by the Company has been estimated using Monte Carlo simulation and or a Black Scholes model. As of October 13, 2016, the Company adopted a sequencing policy whereby all future instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors. The Company records environmental remediation liabilities for properties acquired. The environmental remediation liabilities are initially recorded at fair value. The liability is reduced for actual costs incurred in connection with the clean-up activities for each property. Upon completion of the clean-up, the environmental remediation liability is adjusted to equal the fair value of the remaining operation, maintenance and monitoring activities to be performed for the property. The amount of the additional liability resulting from the completion of the clean-up, if any, would be included in other income (expense). As of June 30, 2017, the Company estimated that the total environmental remediation costs associated with the purchase of the UK Facility will be approximately $ 6.2 6.2 4.5 32.0 The Company reports comprehensive loss and its components in its condensed consolidated financial statements. Comprehensive loss consists of net loss and foreign currency translation adjustments, affecting stockholders’ equity (deficit) that, under U.S, GAAP, are excluded from net loss. Research and development costs are charged to operations as incurred and consist primarily of clinical trial costs, related party manufacturing costs, consulting costs, contract research and development costs, clinical site costs and compensation costs. There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2016 Annual Report. Compensation-Stock Compensation In March 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting Recent Issued Accounting Pronouncements Compensation-Stock Compensation In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting Accounting for Certain Financial Instruments with Down Round Features On July 13, 2017, the FASB has issued a two-part ASU No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	4. Fair Value Measurements Derivative Warrants Granted in 2017 During the six months ended June 30, 2017, the Company issued approximately 94,703,000 2017 Warrants Granted Associated with Public and Private Debt Offering Conversion Issuance of Debt Strike price $ 0.51 $ 0.39 $ 0.18 Contractual term (years) 2.3 2.3 2.0 Volatility (annual) 107 % 109 % 112 % Risk-free rate 1 % 1 % 1 % Dividend yield (per share) 0 % 0 % 0 % Embedded Conversion Features During the six months ended June 30, 2017, the Company recorded approximately $ 4.3 Conversion price $ 0.41 Contractual term (years) 1.92 Volatility (annual) 97 % Risk-free rate 1 % Dividend yield (per share) 0 % Fair value measured at June 30, 2017 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs June 30, 2017 (Level 1) (Level 2) (Level 3) Warrant liability $ 6,878 $ - $ - $ 6,878 Embedded conversion feature 2,075 - - 2,075 Share-settled debt (in default) 4,749 - - 4,749 Total fair value $ 13,702 $ - $ - $ 13,702 Fair value measured at December 31, 2016 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs December 31, 2016 (Level 1) (Level 2) (Level 3) Warrant liability $ 4,862 $ - $ - $ 4,862 Share-settled debt (in default) 5,200 - - 5,200 Total fair value $ 10,062 $ - $ - $ 10,062 There were no transfers between Level 1, 2 or 3 during the six-month period ended June 30, 2017. In accordance with ASC 820, the development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. Warrant Embedded Share-settled Liability Conversion Feature Debt (in Default) Total Balance – January 1, 2017 $ 4,862 $ - $ 5,200 $ 10,062 Warrants granted 9,572 - - 9,572 Issuance of convertible notes - 4,262 - 4,262 Extinguishment of warrant liabilities related to warrants exercised for cash (1,847) - - (1,847) Conversion of share-settled debt - - (451) (451) Change in fair value (5,709) (2,187) - (7,896) Balance – June 30, 2017 $ 6,878 $ 2,075 $ 4,749 $ 13,702 A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities and embedded conversion feature that are categorized within Level 3 of the fair value hierarchy as of June 30, 2017 and December 31, 2016 is as follows: As of June 30, 2017 As of December 31, 2016 Warrant Embedded Warrant Liability Conversion Feature Liability Strike price $ 0.40 $ 0.41 $ 0.60 Contractual term (years) 3.4 1.9 4.7 Volatility (annual) 98 % 99 % 98 % Risk-free rate 2 % 1 % 2 % Dividend yield (per share) 0 % 0 % 0 %

Property & Equipment and Constr

Property & Equipment and Construction in Progress	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	5. Property & Equipment and Construction in Progress June 30, December 31, 2017 2016 Leasehold improvements $ 69 $ 69 Office furniture and equipment 25 25 Computer equipment and software 635 626 729 720 Less: accumulated depreciation (505) (405) Total property, plant and equipment, net 224 315 Construction in progress (property in the United Kingdom) 46,221 44,559 $ 46,445 $ 44,874 * Construction in progress includes both the land acquisition costs and the building costs. Depreciation expenses were approximately $ 100,000 80,000

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	6. Stock-based Compensation On June 13, 2017, the Company granted options (the “Options”) to acquire shares of the Company’s common stock (the “Shares”) to Dr. Marnix Bosch, the Chief Technical Officer of the Company, and Dr. Alton Boynton, the Chief Scientific Officer of the Company. The Options were granted pursuant to the Second Amended and Restated Northwest Biotherapeutics, Inc. 2007 Stock Plan (the “Equity Plan”). The Equity Plan provides for awards of various types of equity securities (including common stock, restricted stock units, options and/or other derivative securities) to employees and directors of the Company. Dr. Bosch received Options exercisable for 7,940,182 3,402,935 0.25 5 50 50% will vest over a 24-month period in equal monthly installments, provided that the recipient continues to be employed by the Company. The unvested portions of the Options are subject to accelerated vesting upon (i) a change of effective control of the Company, (ii) the filing of the first Biologics License Application or other application for product approval in any jurisdiction, (iii) completion of any randomized clinical trial that meets its endpoint(s) (Phase II or Phase III), (iv) decision by the Board, in its discretion or (v) the death of the recipient. The following table summarizes stock option activities for the Company’s option plans for the six months ended June 30, 2017 (amount in thousands, except per share number): Number of Options Weighted Total Intrinsic Weighted Outstanding as of December 31, 2016 1,551 $ 10.56 $ - 1.9 Granted 11,343 0.25 - 5.0 Forfeited/expired (238) 9.90 - - Outstanding as of June 30, 2017 12,656 $ 1.32 - 4.6 Options vested and exercisable 6,546 $ 1.63 $ - 4.5 For the Six Months Ended June 30, 2017 Exercise price $ 0.25 Expected term (years) 2.8 Expected stock price volatility 96 % Risk-free rate of interest 2 % The Company recorded stock based compensation expense of $ 373,000 0.7 0.3 2.2 . The risk-free rate is based on the rate of U.S Treasury zero-coupon issues with a remaining term equal to the expected term of the option grants. Expected volatility is based on the historical volatility of the Company’s common stock using the daily closing price of the Company’s common stock. The expected term represents the period that the Company’s stock-based awards are expected to be outstanding.

Outstanding Debt

Outstanding Debt	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	7. Outstanding Debt Stated Remaining Fair Value of Interest Conversion Debt Debt Embedded Carrying Maturity Date Rate Price Face Value Discount Premium Conversion Option Value Short term convertible notes payable 6% unsecured (1) Due 6 % $ 3.09 135 - - - 135 10% unsecured (2) In Default 10 % $ 0.26 1,578 - - 14 1,592 18% unsecured (3) In Default 18 % $ 0.26 1,183 - 348 237 1,768 2,896 - 348 251 3,495 Short term notes payable 8% unsecured (4) Various 8 % N/A 5,620 (400) - - 5,220 0% unsecured (5) 9/1/2017 0 % N/A 226 (2) - - 224 12% unsecured (5) On Demand 12 % N/A 300 (83) - - 217 6,146 (485) - - 5,661 Short term notes payable - related parties 10% unsecured - Related Parties (6) On Demand 10 % N/A 2,170 - - - 2,170 Share-settled debt, at fair value (7) In Default 18 % $ 0.16 4,749 - - - 4,749 Short term mortgage loan 11/16/2017 12 % N/A 6,225 (110) - - 6,115 Long term convertible notes payable 12% secured convertible notes (8) 6/21/2020 12 % $ 0.50 6,000 (2,443) - 1,826 5,383 Long term mortgage loan (9) 8/13/2018 12 % N/A 4,478 (25) - - 4,453 Ending balance as of June 30, 2017 32,664 (3,063) 348 2,077 32,026 Stated Remaining Interest Conversion Debt Carrying Maturity Date Rate Price Face Value Discount Value Short term convertible notes payable 6% unsecured (1) Due 6 % $ 3.09 $ 135 $ - $ 135 5% 2014 Senior convertible notes (8) 8/15/2017 5 % $ 6.60 11,000 (175) 10,825 11,135 (175) 10,960 Short term notes payable 10% unsecured (2) 11/4/2017 10 % N/A 2,450 - 2,450 Short term notes payable - related parties 10% unsecured - Related Parties On Demand 10 % N/A 50 - 50 12% unsecured - Related Parties On Demand 12 % N/A 260 - 260 310 - 310 Share-settled debt, at fair value (7) In Default 18 % $ 0.35 5,200 - 5,200 Mortgage loan 11/16/17 & 8/13/17 12 % N/A 10,156 (365) 9,791 Long term note payable 8% unsecured note (4) 6/30/2018 8 % N/A 3,310 (310) 3,000 Ending balance as of December 31, 2016 $ 32,561 $ (850) $ 31,711 (1) This $ 135,000 110,000 25,000 110,000 25,000 (2) On November 4, 2016, the Company entered into three promissory notes agreement (“the Notes”) with an individual investor (“the Holder”) for an aggregate amount of $ 2.45 10 1 On April 12, 2017, the Company entered a note amendment (“the Amendment”) with the Holder. The maturity date was amended to June 30, 2017, and the Holder was granted an option to convert outstanding principal amount and accrued interest into a package of (i) one share of common stock at conversion price of $0.26, (ii) 0.75 of a warrant with a strike price of $0.26 with a 5 years term, and (iii) 0.75 of a warrant with a strike price of $1.00 with a 3 months term. The Company recorded approximately $ 1.4 14,000 On May 22, 2017, the Company induced the holder to convert approximately $ 872,000 128,000 5,555,556 0.16 8,333,334 0.11 349 (3) On March 3, 2017, the Company entered into a series of promissory notes (the “OID Notes”) with unrelated third parties (the “Holders”) in the original principal amount of $ 1,450,000 3 1.4 On April 10, 2017, the Company entered into multiple note amendments (“the Amendment”) with the OID Notes holders. The maturity date was amended to June 10, 2017, and the Holders were granted the option to convert outstanding principal amount and accrued interest into a package of (i) one share of common stock at the conversion price of $0.26, (ii) 0.75 of a warrant with a strike price of $0.26 with a 5 years term, and (iii) 0.75 of a warrant with a strike price of $1.00 with a 3 months term. The Company recorded approximately $ 1.0 237,000 On April 12, 2017, the Company made a repayment of $ 258,000 The Company accrued an additional $ 348,000 (4) During six months ended June 30, 2017, the Company entered into two promissory notes agreement (the “Notes”) with the same investor for an aggregate principal amount of $ 2,310,000 8 6 300,000 10,000 186,000 On December 30, 2016, the Company entered into a note purchase agreement (the “Note”) with an individual investor for an aggregate principal amount of $ 3,310,000 8 18 300,000 10,000 214,000 (5) On June 29, 2017, the Company entered into a promissory note (the “Note”) agreement with an investor for the amount of $ 300,000 12 833,333 0.18 84,000 On March 1, 2017, the Company entered into a promissory note (the “Note”) agreement with an investor in the original principal amount of $ 226,000 3 220,000 (6) Related Party Notes Goldman Notes During the quarter ended June 30, 2017, Leslie J. Goldman, an officer of the Company, loaned the Company an aggregate amount of $ 850,000 10 7 During the quarter ended March 31, 2017, Leslie J. Goldman, an officer of the Company, loaned the Company $ 420,000 12 During the six months ended June 30, 2017, the Company made an aggregate principal payment of $ 730,000 47,000 Toucan Notes During the quarter ended June 30, 2017, Toucan Capital Fund III loaned the Company an aggregate amount of $ 1,170,000 10 7 150,000 Board of Directors Notes During the quarter ended June 30, 2017, Jerry Jasinowski, Robert Farmer and Cofer Black, members of the Company’s Board of Directors, loaned the Company an aggregate amount of $ 300,000 10 7 (7) During the six months ended June 30, 2016, the holder of the Company’s share-settled debt converted approximately $ 0.5 (8) 2014 Senior Convertible Notes Due to the Nasdaq delisting on December 19, 2016, the term of the 2014 Convertible Senior Notes (the “2014 Notes”) Indenture required the Company to offer to repurchase the entire principal and all remaining interest through the Notes’ original maturity date. The debt holders (the “Holders”) accepted the offer, and the Company was required to repurchase the entire 2014 Notes on March 10, 2017. The full repurchase of $ 11 660,000 During the six months ended June 30, 2017, the Company entered into multiple agreements to extend the date for payment of the 2014 Notes to June 20, 2017. As an additional consideration to the Holders to delay the 2014 Notes repayment, the Company issued the Holders an aggregate 7,089,860 2.6 2.1 0.5 During the six months ended June 30, 2017, the Company repaid in cash $ 3.0 3.0 5 2017 Secured Convertible Notes On June 21, 2017, an unaffiliated institutional investor (the “Investor”) agreed to purchase $5.0 million of the 2014 Notes from the Holders, pursuant to a Purchase Agreement (the “Purchase Agreement”). Also on June 21, 2017, the Company and the Investor entered into an Exchange Agreement (the “Exchange Agreement”) pursuant to which the Investor agreed to exchange its $ 5.0 5.6 9 350,000 9 325,000 6.0 The 2017 Notes have a 3 12 1.8 (9) The mortgage loan, which was originally due in August 2017 and has been renewed for additional one year until August 17, 2018. For the three months ended For the six months ended June 30, June 30, 2017 2016 2017 2016 Interest expenses related to 2014 Senior convertible notes: Contractual interest $ 39 $ 137 $ 424 $ 274 Amortization of debt issuance costs - 70 175 140 Total interest expenses related to senior convertible notes 39 207 599 414 Interest expenses related to other notes: Contractual interest 245 38 389 76 Additional debt premium 348 - 348 - Amortization of debt discount 190 - 270 - Total interest expenses related to other notes 783 38 1,007 76 Interest expenses related to mortgage loan: Contractual interest 360 332 649 665 Amortization of debt issuance costs 123 152 242 291 Total interest expenses on the mortgage loan 483 484 891 956 Other interest expenses 3 - 5 1 Total interest expense $ 1,308 $ 729 $ 2,502 $ 1,447

Net Loss per Share Applicable t

Net Loss per Share Applicable to Common Stockholders	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	8. Net Loss per Share Applicable to Common Stockholders Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similar to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. For the six months ended June 30, 2017 2016 Common stock options 12,656 1,551 Common stock warrants - equity treatment 37,554 23,276 Common stock warrants - liability treatment 84,135 21,169 Share-settled debt and accrued interest, at fair value 30,932 - Convertible notes and accrued interest 27,501 1,764 Potentially dilutive securities 192,778 47,760

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9. Related Party Transactions Cognate BioServices, Inc. Cognate Expenses and Accounts Payable At June 30, 2017 and December 31, 2016, the Company owed Cognate $ 21.4 3.75 23.4 During the quarter ended June 30, 2017, Cognate waived its right to receive payment of $ 3.75 Overall, for the three months ended June 30, 2017 and 2016, the Company incurred research and development costs related to Cognate BioServices of $ 2.6 5.5 Overall, for the six months ended June 30, 2017 and 2016, the Company incurred research and development costs related to Cognate BioServices of $ 5.2 16.6 Cognate Organization Pursuant to an institutional financing of Cognate in October 2016, Cognate’s operations outside the US were separated from its operations in the US. The operations outside the US include Cognate BioServices GmbH in Germany, Advent BioServices, Ltd (formerly called 1.5 2.3 Other Related Parties Leslie J. Goldman - Demand Loans During the three months ended March 31, 2017, Leslie J. Goldman, an officer of the Company, loaned the Company $ 420,000 12 During the three months ended June 30, 2017, Mr. Goldman loaned the Company an additional $ 850,000 10 During the six months ended June 30, 2017, the Company made an aggregate principal payment of $ 730,000 47,000 Toucan Capital III Fund - Demand Loans During the three months ended June 30, 2017, Toucan Capital Fund III loaned the Company an aggregate amount of $ 1,170,000 10 In June 2017, the Company made repayment of $ 150,000 Various Related Parties - Demand Loans During the three months ended June 30, 2017, Jerry Jasinowski, Robert Farmer and Cofer Black, members of the Company’s Board of Directors, loaned the Company an aggregate amount of $ 300,000 10

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	10. Stockholders’ Equity (Deficit) Common Stock Issuances First Quarter of 2017 Public Offering On March 17, 2017, the Company entered into agreements with institutional investors for a registered direct offering with gross proceeds of $ 7.5 18.8 0.26 5 21.6 0.26 21.6 1.00 10.0 0.26 0.25 6.2 Warrants Exercised for Cash During the quarter ended March 31, 2017, the Company issued an aggregate of 3,100,000 31 713,000 Stock Compensation - 2014 Senior Convertible Notes On March 10, 2017, the Company issued 4,039,860 11 1.5 Share-settled Debt On March 30, 2017, the Company issued 2,500,000 Second Quarter of 2017 Public and Private Offering On April 14, 2017, the Company entered into Stock Purchase Agreement with multiple investors. The Company issued 1,384,615 0.26 1,038,461 0.26 1,038,461 1.00 five three 360,000 During the three months ended June 30, 2017, the Company entered into Subscription Agreements with multiple investors. The Company issued 3,610,452 0.15 3,274,553 0.33 552,000 Debt Conversion On May 22, 2017, the holders of certain existing notes converted approximately $ 2.0 11,137,345 0.18 8,353,009 0.26 5 8,353,009 1.00 90 1.8 0.9 On May 31, 2017, the Company and certain unaffiliated institutional investors (the “Investor”) entered into an Exchange Agreement (the “Exchange Agreement”) pursuant to which the Investor agreed to exchange $ 3.0 20,628,571 16,071,428 0.175 2 800,000 3.9 1.6 On June 5, 2017, the Company exchanged approximately $ 0.5 3,300,000 0.14 2,475,000 0.175 2 0.6 0.3 Warrants Exercised for Cash During the three months ended June 30, 2017, the Company issued an aggregate of 6,900,000 with an exercise price of $ 0.26 0.25 0.01 was paid at the time of 69 at the time of exercise during the three months ended June 30, 2017. 1.1 Stock Compensation - 2014 Senior Convertible Notes During the three months ended June 30, the Company issued an aggregate of 3,050,000 11 Share-settled Debt On June 14, 2017, the Company issued 1,000,000 As of June 30, 2017, the outstanding share-settled debt was approximately $ 4.7 Stock Purchase Warrants Number of Weighted Average Remaining Warrants Exercise Price Contractual Term Outstanding as of January 1, 2017 58,278 $ 1.78 3.86 Warrants granted * 96,530 0.48 Warrants exercised for cash (10,800) 0.02 Warrants expired and cancellation (22,319) 1.24 Outstanding as of June 30, 2017 121,689 $ 0.98 3.10 * Including approximately 1.0 The Company’s adoption of a sequencing policy in the fourth quarter of 2016 requires that all financial instruments issued subsequent to such adoption be treated as a derivative liability. As such, warrants issued in the current period report have been classified as liabilities.

Variable Interest Entities

Variable Interest Entities	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Variable Interest Entity Disclosure [Text Block]	11. Variable Interest Entities Variable Interest Entities (“VIEs”) are entities in which equity investors lack the characteristics of a controlling financial interest. VIEs are consolidated by the primary beneficiary. The primary beneficiary is the party who has both the power to direct the activities of a VIE that most significantly impact the entity’s economic performance and an obligation to absorb losses of the entity or a right to receive benefits from the entity that could potentially be significant to the entity. After the assumption of $ 5.7 The maximum exposure to loss is limited to the notional amounts of the implicit variable interest in Cognate. The Company has no current plans to provide any support additional to that which is noted above. Therefore, the maximum exposure to loss from its implicit interest is limited to $ 4.5

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	12. Commitments and Contingencies Contingent Payment to Cognate BioServices Under the January 17, 2014 DCVax®-L Manufacturing Services Agreement and the DCVax-Direct Agreement, a new set of provisions apply going forward to any shut down or suspension. Under these provisions, the Company will be contingently obligated to pay certain fees to Cognate BioServices (in addition to any other remedies) if the Company shuts down or suspends its DCVax-L program or DCVax-Direct program. For a shutdown or suspension of the DCVax-L program, the fees will be as fol l ⋅ Prior to the last dose of the last patient enrolled in the Phase III trial for DCVax®-L or After the last dose of the last patient enrolled in the Phase III clinical trial for DCVax®-L but before any submission for product approval in any jurisdiction or After the submission of any application for market authorization but prior to receiving a marketing authorization approval: in any of these cases, the fee shall be $ 3 ⋅ At any time after receiving the equivalent of a marketing authorization for DCVax®-L in any jurisdiction, the fee shall be $ 5 For a shutdown or suspension of the DCVax-Direct program, the fees will be as follows: ⋅ Prior to the last dose of the last patient enrolled in the Phase I/II trial for DCVax®-Direct, the fee shall be $ 1.5 ⋅ After the last dose of the last patient enrolled in the Phase I/II clinical trial for DCVax®-Direct but before the initiation of a Phase III trial the fee shall be $ 2.0 ⋅ After initiation of a phase III trial but before submission of an application for market authorization in any jurisdiction or After the submission of an application for market authorization but prior to receiving a market authorization approval: in each of these cases, the fee shall be $ 3.0 ⋅ At any time after receiving the equivalent of a marketing authorization for DCVax®-Direct in any jurisdiction the fee shall be $ 5.0 As of June 30, 2017, none of the above fees were triggered. While our DCVax programs are ongoing, the Company is required to pay certain fees for dedicated production suites or capacity reserved exclusively for DCVax production, and pay for a certain minimum number of patients, whether or not we fully utilize the dedicated capacity and number of patients. The Company and Cognate are testing an arrangement under which the Company would no longer have capacity dedicated to its programs and instead would have to arrange for advance scheduling in regard to each patient individually. Derivative and Class Action Litigation On June 19, 2015, two purported shareholders filed a lawsuit in the Delaware Court of Chancery, captioned Tharp, et al. v. Cognate, et al. Yonemura On November 19, 2015, a third purported shareholder filed a lawsuit in the U.S. District Court for the District of Maryland, captioned Yonemura v. Powers, et al. Yonemura Tharp Yonemura Tharp Tharp Yonemura On November 28, 2016, a purported shareholder filed a lawsuit in the Circuit Court for Montgomery County, Maryland, captioned Wells v. Powers, et al. Class Action Securities Litigation On August 26, 2015, a purported shareholder of the Company filed a putative class action lawsuit in the U.S. District Court for the District of Maryland, captioned Lerner v. Northwest Biotherapeutics, Inc., et al. U.S. Securities and Exchange Commission As previously reported, the Company has received a number formal information requests (subpoenas) from the SEC regarding several broad topics that have been previously disclosed, including the Company’s membership on Nasdaq and delisting, related party matters, the Company’s programs, internal controls and the Company’s Special Litigation Committee. Testimony of certain officers and third parties has been taken as well. The Company is cooperating with the SEC investigation and is hopeful that it is reaching its final stages. Unfortunately, the investigation has been costly for the Company, both in terms of professional fees and in distraction of management from operation of the Company and its programs. Special Litigation Committee As previously reported, the Company appointed a Special Litigation Committee, and Committee has undertaken an inquiry into the allegations of various lawsuits filed against the Company, and an anonymous internet report raising a number of criticisms of the Company and its Board and management, including with respect to the reasonableness of the transactions with Cognate. The Committee has retained experts to analyze some of these issues. Chardan Capital Markets v. Northwest Biotherapeutics, Inc. On June 22, 2017, Chardan Capital Markets, LLC filed a lawsuit against the Company in the United District Court for the Southern District of New York, captioned Chardan Capital Markets v. Northwest Biotherapeutics, Inc., 1:17-cv-04727-PKC. Chardan alleges that it provided capital placement agent services to the Company in December 2016 under a contract and that it has not been fully compensated for those services. Chardan further alleges that it provided additional services to the Company in March 2017 in anticipation of entering into contract and that it received no compensation. The complaint asserts claims for breach of contract and unjust enrichment, and purports to seek “at least” $1 million, interest, and attorneys’ fees and costs. 446,000

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	13. Subsequent Events During July and August, 2017, the Company raised additional gross funding of $ 4.6 Public and Private Offering On July 11, 2017, the Company sold to an unaffiliated investor 200,000 0.16 150,000 0.175 2 32,000 On August 1, 2017, the Company entered into a $ 1 5.0 0.20 2.5 0.23 0.30 Debt Offering During July and August 2017, the Company entered into multiple demand note agreements with investors for total proceeds of $ 0.9 Warrants Exercised for Cash and Warrants Modification On August 7, 2017, the Company entered into a $ 2.7 13,527,000 1.00 0.20 90 13,527,000 0.27 5 Cashless Warrants Exercise On July 17, 2017, holders of 16,071,428 6,939,934 On July 17, 2017, the Company extended the expiration date of 1,038,460 1.00 Debt Conversions On July 17, 2017, the Company exchanged approximately $ 1.6 36,000 10,086,853 0.16 7,565,139 0.18 5 7,565,139 1.00 90 On July 10, 2017, the Company exchanged approximately $ 412 3,335,730 0.12 On August 1, 2017, the Company exchanged approximately $ 1.2 407,000 39,000 9,059,107 0.18 13,588,663 0.18 5 6,794,333 1.00 90 On August 4, 2017, the Company exchanged approximately $ 1.0 5.0 0.20 2,442,890 0.23 2 2,442,890 0.30 2 Share-settled Debt From July to August, the Company issued 3,500,000 Such common shares were not sold by the Holder as of June 30, 2017. Therefore the Company didn’t reduce the share-settled debt balance upon issuance of such shares. Shares for Services On July 6, 2017, as compensation for services as a Director, the Company issued 1,312,500 0.16

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated. Certain immaterial reclassifications have been made to prior period amounts to conform to the current period presentation. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of June 30, 2017, condensed consolidated statements of operations for the three and six months ended June 30, 2017 and 2016, condensed consolidated statements of comprehensive loss for the six months ended June 30, 2017 and 2016, condensed consolidated statement of stockholders’ equity (deficit) for the six months ended June 30, 2017, and the condensed consolidated statements of cash flows for the six months ended June 30, 2017 and 2016 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and six months ended June 30, 2017 are not necessarily indicative of results to be expected for the year ending December 31, 2017 or for any future interim period. The condensed consolidated balance sheet at December 31, 2016 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2016, and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on April 17, 2017.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates In preparing condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, valuing environmental liabilities, estimating the fair value of financial instruments recorded as derivative liabilities, and estimating the useful lives of depreciable assets and whether impairment charges may apply.
Warrant Liability Policy [Policy Text Block]	Warrant Liability The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company's statements of operations. The fair value of the warrants issued by the Company has been estimated using Monte Carlo simulation and or a Black Scholes model.
Sequencing [Policy Text Block]	Sequencing As of October 13, 2016, the Company adopted a sequencing policy whereby all future instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors.
Environmental Cost, Expense Policy [Policy Text Block]	Environmental Remediation Liabilities The Company records environmental remediation liabilities for properties acquired. The environmental remediation liabilities are initially recorded at fair value. The liability is reduced for actual costs incurred in connection with the clean-up activities for each property. Upon completion of the clean-up, the environmental remediation liability is adjusted to equal the fair value of the remaining operation, maintenance and monitoring activities to be performed for the property. The amount of the additional liability resulting from the completion of the clean-up, if any, would be included in other income (expense). As of June 30, 2017, the Company estimated that the total environmental remediation costs associated with the purchase of the UK Facility will be approximately $ 6.2 6.2 4.5 32.0
Comprehensive Loss Policy [Policy Text Block]	Comprehensive Loss The Company reports comprehensive loss and its components in its condensed consolidated financial statements. Comprehensive loss consists of net loss and foreign currency translation adjustments, affecting stockholders’ equity (deficit) that, under U.S, GAAP, are excluded from net loss.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development costs are charged to operations as incurred and consist primarily of clinical trial costs, related party manufacturing costs, consulting costs, contract research and development costs, clinical site costs and compensation costs.
Significant Accounting Policies [Policy Text Block]	Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2016 Annual Report.
New Accounting Pronouncements, Policy [Policy Text Block]	Adoption of Recent Accounting Pronouncements Compensation-Stock Compensation In March 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting Recent Issued Accounting Pronouncements Compensation-Stock Compensation In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting Accounting for Certain Financial Instruments with Down Round Features On July 13, 2017, the FASB has issued a two-part ASU No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table presents changes in Level 3 liabilities measured at fair value for the six-month period ended June 30, 2017. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (in thousands). Warrant Embedded Share-settled Liability Conversion Feature Debt (in Default) Total Balance – January 1, 2017 $ 4,862 $ - $ 5,200 $ 10,062 Warrants granted 9,572 - - 9,572 Issuance of convertible notes - 4,262 - 4,262 Extinguishment of warrant liabilities related to warrants exercised for cash (1,847) - - (1,847) Conversion of share-settled debt - - (451) (451) Change in fair value (5,709) (2,187) - (7,896) Balance – June 30, 2017 $ 6,878 $ 2,075 $ 4,749 $ 13,702
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities and embedded conversion feature that are categorized within Level 3 of the fair value hierarchy as of June 30, 2017 and December 31, 2016 is as follows: As of June 30, 2017 As of December 31, 2016 Warrant Embedded Warrant Liability Conversion Feature Liability Strike price $ 0.40 $ 0.41 $ 0.60 Contractual term (years) 3.4 1.9 4.7 Volatility (annual) 98 % 99 % 98 % Risk-free rate 2 % 1 % 2 % Dividend yield (per share) 0 % 0 % 0 %
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of June 30, 2017 and December 31, 2016 (in thousands): Fair value measured at June 30, 2017 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs June 30, 2017 (Level 1) (Level 2) (Level 3) Warrant liability $ 6,878 $ - $ - $ 6,878 Embedded conversion feature 2,075 - - 2,075 Share-settled debt (in default) 4,749 - - 4,749 Total fair value $ 13,702 $ - $ - $ 13,702 Fair value measured at December 31, 2016 Quoted prices in active Significant other Significant Fair value at markets observable inputs unobservable inputs December 31, 2016 (Level 1) (Level 2) (Level 3) Warrant liability $ 4,862 $ - $ - $ 4,862 Share-settled debt (in default) 5,200 - - 5,200 Total fair value $ 10,062 $ - $ - $ 10,062
Embedded Derivative Financial Instruments [Member]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	A summary of weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring warrants granted during the six months ended June 30, 2017 is as follows: Conversion price $ 0.41 Contractual term (years) 1.92 Volatility (annual) 97 % Risk-free rate 1 % Dividend yield (per share) 0 %
Warrant [Member] | Public and Private Offering [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	A summary of weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring warrants granted during the six months ended June 30, 2017 is as follows: 2017 Warrants Granted Associated with Public and Private Debt Offering Conversion Issuance of Debt Strike price $ 0.51 $ 0.39 $ 0.18 Contractual term (years) 2.3 2.3 2.0 Volatility (annual) 107 % 109 % 112 % Risk-free rate 1 % 1 % 1 % Dividend yield (per share) 0 % 0 % 0 %

Property & Equipment and Cons24

Property & Equipment and Construction in Progress (Tables)	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	June 30, December 31, 2017 2016 Leasehold improvements $ 69 $ 69 Office furniture and equipment 25 25 Computer equipment and software 635 626 729 720 Less: accumulated depreciation (505) (405) Total property, plant and equipment, net 224 315 Construction in progress (property in the United Kingdom) 46,221 44,559 $ 46,445 $ 44,874

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes stock option activities for the Company’s option plans for the six months ended June 30, 2017 (amount in thousands, except per share number): Number of Options Weighted Total Intrinsic Weighted Outstanding as of December 31, 2016 1,551 $ 10.56 $ - 1.9 Granted 11,343 0.25 - 5.0 Forfeited/expired (238) 9.90 - - Outstanding as of June 30, 2017 12,656 $ 1.32 - 4.6 Options vested and exercisable 6,546 $ 1.63 $ - 4.5
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following assumptions were used to compute the fair value of stock options granted during the six months ended June 30, 2017: For the Six Months Ended June 30, 2017 Exercise price $ 0.25 Expected term (years) 2.8 Expected stock price volatility 96 % Risk-free rate of interest 2 %

Outstanding Debt (Tables)

Outstanding Debt (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	The following table summarizes outstanding debt as of June 30, 2017 and December 31, 2016, respectively (amount in thousands, except per share data): Stated Remaining Fair Value of Interest Conversion Debt Debt Embedded Carrying Maturity Date Rate Price Face Value Discount Premium Conversion Option Value Short term convertible notes payable 6% unsecured (1) Due 6 % $ 3.09 135 - - - 135 10% unsecured (2) In Default 10 % $ 0.26 1,578 - - 14 1,592 18% unsecured (3) In Default 18 % $ 0.26 1,183 - 348 237 1,768 2,896 - 348 251 3,495 Short term notes payable 8% unsecured (4) Various 8 % N/A 5,620 (400) - - 5,220 0% unsecured (5) 9/1/2017 0 % N/A 226 (2) - - 224 12% unsecured (5) On Demand 12 % N/A 300 (83) - - 217 6,146 (485) - - 5,661 Short term notes payable - related parties 10% unsecured - Related Parties (6) On Demand 10 % N/A 2,170 - - - 2,170 Share-settled debt, at fair value (7) In Default 18 % $ 0.16 4,749 - - - 4,749 Short term mortgage loan 11/16/2017 12 % N/A 6,225 (110) - - 6,115 Long term convertible notes payable 12% secured convertible notes (8) 6/21/2020 12 % $ 0.50 6,000 (2,443) - 1,826 5,383 Long term mortgage loan (9) 8/13/2018 12 % N/A 4,478 (25) - - 4,453 Ending balance as of June 30, 2017 32,664 (3,063) 348 2,077 32,026 Stated Remaining Interest Conversion Debt Carrying Maturity Date Rate Price Face Value Discount Value Short term convertible notes payable 6% unsecured (1) Due 6 % $ 3.09 $ 135 $ - $ 135 5% 2014 Senior convertible notes (8) 8/15/2017 5 % $ 6.60 11,000 (175) 10,825 11,135 (175) 10,960 Short term notes payable 10% unsecured (2) 11/4/2017 10 % N/A 2,450 - 2,450 Short term notes payable - related parties 10% unsecured - Related Parties On Demand 10 % N/A 50 - 50 12% unsecured - Related Parties On Demand 12 % N/A 260 - 260 310 - 310 Share-settled debt, at fair value (7) In Default 18 % $ 0.35 5,200 - 5,200 Mortgage loan 11/16/17 & 8/13/17 12 % N/A 10,156 (365) 9,791 Long term note payable 8% unsecured note (4) 6/30/2018 8 % N/A 3,310 (310) 3,000 Ending balance as of December 31, 2016 $ 32,561 $ (850) $ 31,711 (1) This $ 135,000 110,000 25,000 110,000 25,000 (2) On November 4, 2016, the Company entered into three promissory notes agreement (“the Notes”) with an individual investor (“the Holder”) for an aggregate amount of $ 2.45 10 1 On April 12, 2017, the Company entered a note amendment (“the Amendment”) with the Holder. The maturity date was amended to June 30, 2017, and the Holder was granted an option to convert outstanding principal amount and accrued interest into a package of (i) one share of common stock at conversion price of $0.26, (ii) 0.75 of a warrant with a strike price of $0.26 with a 5 years term, and (iii) 0.75 of a warrant with a strike price of $1.00 with a 3 months term. The Company recorded approximately $ 1.4 14,000 On May 22, 2017, the Company induced the holder to convert approximately $ 872,000 128,000 5,555,556 0.16 8,333,334 0.11 349 (3) On March 3, 2017, the Company entered into a series of promissory notes (the “OID Notes”) with unrelated third parties (the “Holders”) in the original principal amount of $ 1,450,000 3 1.4 On April 10, 2017, the Company entered into multiple note amendments (“the Amendment”) with the OID Notes holders. The maturity date was amended to June 10, 2017, and the Holders were granted the option to convert outstanding principal amount and accrued interest into a package of (i) one share of common stock at the conversion price of $0.26, (ii) 0.75 of a warrant with a strike price of $0.26 with a 5 years term, and (iii) 0.75 of a warrant with a strike price of $1.00 with a 3 months term. The Company recorded approximately $ 1.0 237,000 On April 12, 2017, the Company made a repayment of $ 258,000 The Company accrued an additional $ 348,000 (4) During six months ended June 30, 2017, the Company entered into two promissory notes agreement (the “Notes”) with the same investor for an aggregate principal amount of $ 2,310,000 8 6 300,000 10,000 186,000 On December 30, 2016, the Company entered into a note purchase agreement (the “Note”) with an individual investor for an aggregate principal amount of $ 3,310,000 8 18 300,000 10,000 214,000 (5) On June 29, 2017, the Company entered into a promissory note (the “Note”) agreement with an investor for the amount of $ 300,000 12 833,333 0.18 84,000 On March 1, 2017, the Company entered into a promissory note (the “Note”) agreement with an investor in the original principal amount of $ 226,000 3 220,000 (6) Related Party Notes Goldman Notes During the quarter ended June 30, 2017, Leslie J. Goldman, an officer of the Company, loaned the Company an aggregate amount of $ 850,000 10 7 During the quarter ended March 31, 2017, Leslie J. Goldman, an officer of the Company, loaned the Company $ 420,000 12 During the six months ended June 30, 2017, the Company made an aggregate principal payment of $ 730,000 47,000 Toucan Notes During the quarter ended June 30, 2017, Toucan Capital Fund III loaned the Company an aggregate amount of $ 1,170,000 10 7 150,000 Board of Directors Notes During the quarter ended June 30, 2017, Jerry Jasinowski, Robert Farmer and Cofer Black, members of the Company’s Board of Directors, loaned the Company an aggregate amount of $ 300,000 10 7 (7) During the six months ended June 30, 2016, the holder of the Company’s share-settled debt converted approximately $ 0.5 (8) 2014 Senior Convertible Notes Due to the Nasdaq delisting on December 19, 2016, the term of the 2014 Convertible Senior Notes (the “2014 Notes”) Indenture required the Company to offer to repurchase the entire principal and all remaining interest through the Notes’ original maturity date. The debt holders (the “Holders”) accepted the offer, and the Company was required to repurchase the entire 2014 Notes on March 10, 2017. The full repurchase of $ 11 660,000 During the six months ended June 30, 2017, the Company entered into multiple agreements to extend the date for payment of the 2014 Notes to June 20, 2017. As an additional consideration to the Holders to delay the 2014 Notes repayment, the Company issued the Holders an aggregate 7,089,860 2.6 2.1 0.5 During the six months ended June 30, 2017, the Company repaid in cash $ 3.0 3.0 5 2017 Secured Convertible Notes On June 21, 2017, an unaffiliated institutional investor (the “Investor”) agreed to purchase $5.0 million of the 2014 Notes from the Holders, pursuant to a Purchase Agreement (the “Purchase Agreement”). Also on June 21, 2017, the Company and the Investor entered into an Exchange Agreement (the “Exchange Agreement”) pursuant to which the Investor agreed to exchange its $ 5.0 5.6 9 350,000 9 325,000 6.0 The 2017 Notes have a 3 12 1.8 (9) The mortgage loan, which was originally due in August 2017 and has been renewed for additional one year until August 17, 2018.
Interest Income and Interest Expense Disclosure [Table Text Block]	The following table summarizes total interest expenses related to senior convertible notes, other notes and mortgage loan for the three and six months ended June 30, 2017 and 2016, respectively (in thousands): For the three months ended For the six months ended June 30, June 30, 2017 2016 2017 2016 Interest expenses related to 2014 Senior convertible notes: Contractual interest $ 39 $ 137 $ 424 $ 274 Amortization of debt issuance costs - 70 175 140 Total interest expenses related to senior convertible notes 39 207 599 414 Interest expenses related to other notes: Contractual interest 245 38 389 76 Additional debt premium 348 - 348 - Amortization of debt discount 190 - 270 - Total interest expenses related to other notes 783 38 1,007 76 Interest expenses related to mortgage loan: Contractual interest 360 332 649 665 Amortization of debt issuance costs 123 152 242 291 Total interest expenses on the mortgage loan 483 484 891 956 Other interest expenses 3 - 5 1 Total interest expense $ 1,308 $ 729 $ 2,502 $ 1,447

Net Loss per Share Applicable27

Net Loss per Share Applicable to Common Stockholders (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented (in thousands): For the six months ended June 30, 2017 2016 Common stock options 12,656 1,551 Common stock warrants - equity treatment 37,554 23,276 Common stock warrants - liability treatment 84,135 21,169 Share-settled debt and accrued interest, at fair value 30,932 - Convertible notes and accrued interest 27,501 1,764 Potentially dilutive securities 192,778 47,760

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Schedule Of Warrant Activity [Table Text Block]	Number of Weighted Average Remaining Warrants Exercise Price Contractual Term Outstanding as of January 1, 2017 58,278 $ 1.78 3.86 Warrants granted * 96,530 0.48 Warrants exercised for cash (10,800) 0.02 Warrants expired and cancellation (22,319) 1.24 Outstanding as of June 30, 2017 121,689 $ 0.98 3.10 * Including approximately 1.0

Liquidity, Financial Conditio29

Liquidity, Financial Condition and Management Plans (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Net Cash Provided by (Used in) Operating Activities, Continuing Operations			$ (15,976)	$ (31,801)
Current Assets Less Payables	$ 72,000		72,000
Net Income (Loss) Attributable To Parent	(10,253)	$ (14,175)	(22,873)	$ (20,281)
Accounts Payable, Related Parties, Current	21,400		21,400
Assets, Current, Total	819		819		$ 7,884
Proceeds from Issuance of Common Stock and Debt			16,000
Trade Liabilities Waived by Related Parties, Amount	$ 3,750		3,750
Debt Instrument, Increase (Decrease), Net			$ 5,000

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details Textual) $ in Millions	6 Months Ended
	Jun. 30, 2017USD ($)
Summary of Significant Accounting Policies [Line Items]
Accrued Environmental Loss Contingencies, Noncurrent	$ 6.2
Site Contingency, Loss Exposure in Excess of Accrual, Best Estimate	6.2
Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Site Contingency, Loss Exposure in Excess of Accrual, Best Estimate	32
Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Site Contingency, Loss Exposure in Excess of Accrual, Best Estimate	$ 4.5

Fair Value Measurements (Detail

Fair Value Measurements (Details)	6 Months Ended
	Jun. 30, 2017$ / shares
Issuance of Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price	$ 0.39
Contractual term (years)	2 years 3 months 18 days
Volatility (annual)	109.00%
Risk-free rate	1.00%
Dividend yield (per share)	0.00%
Private and Public Offering [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price	$ 0.51
Contractual term (years)	2 years 3 months 18 days
Volatility (annual)	107.00%
Risk-free rate	1.00%
Dividend yield (per share)	0.00%
Debt Conversion [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price	$ 0.18
Contractual term (years)	2 years
Volatility (annual)	112.00%
Risk-free rate	1.00%
Dividend yield (per share)	0.00%

Fair Value Measurements (Deta32

Fair Value Measurements (Details 1) - Embedded Derivative Financial Instruments [Member]	6 Months Ended
	Jun. 30, 2017$ / shares
Conversion price	$ 0.41
Contractual term (years)	1 year 11 months 1 day
Volatility (annual)	97.00%
Risk-free rate	1.00%
Dividend yield (per share)	0.00%

Fair Value Measurements (Deta33

Fair Value Measurements (Details 2) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 6,878	$ 4,862
Embedded conversion feature	2,075
Share-settled debt (in default)	4,749	5,200
Total fair value	13,702	10,062
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	0	0
Embedded conversion feature	0
Share-settled debt (in default)	0	0
Total fair value	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	0	0
Embedded conversion feature	0
Share-settled debt (in default)	0	0
Total fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	6,878	4,862
Embedded conversion feature	2,075
Share-settled debt (in default)	4,749	5,200
Total fair value	$ 13,702	$ 10,062

Fair Value Measurements (Deta34

Fair Value Measurements (Details 3) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	$ 10,062
Warrants granted	9,572
Issuance of convertible notes	4,262
Extinguishment of warrant liabilities related to warrants exercised for cash	(1,847)
Conversion of share-settled debt	(451)
Change in fair value	(7,896)
Balance	13,702
Long-term Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	5,200
Warrants granted	0
Issuance of convertible notes	0
Extinguishment of warrant liabilities related to warrants exercised for cash	0
Conversion of share-settled debt	(451)
Change in fair value	0
Balance	4,749
Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	4,862
Warrants granted	9,572
Issuance of convertible notes	0
Extinguishment of warrant liabilities related to warrants exercised for cash	(1,847)
Conversion of share-settled debt	0
Change in fair value	(5,709)
Balance	6,878
Embedded Derivative Financial Instruments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	0
Warrants granted	0
Issuance of convertible notes	4,262
Extinguishment of warrant liabilities related to warrants exercised for cash	0
Conversion of share-settled debt	0
Change in fair value	(2,187)
Balance	$ 2,075

Fair Value Measurements (Deta35

Fair Value Measurements (Details 4) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Embedded Derivative Financial Instruments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price	$ 0.41
Contractual term (years)	1 year 11 months 1 day
Volatility (annual)	97.00%
Risk-free rate	1.00%
Dividend yield (per share)	0.00%
Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Strike price	$ 0.40	$ 0.60
Contractual term (years)	3 years 4 months 24 days	4 years 8 months 12 days
Volatility (annual)	98.00%	98.00%
Risk-free rate	2.00%	2.00%
Dividend yield (per share)	0.00%	0.00%

Fair Value Measurements (Deta36

Fair Value Measurements (Details Textual) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability | $	$ 2,075
Jerry Jasinowski [Member] | Investor [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Warrant Issue During Period | shares	94,703,000

Property & Equipment and Cons37

Property & Equipment and Construction in Progress (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Property, plant and equipment, gross	$ 729	$ 720
Less: accumulated depreciation	(505)	(405)
Total property, plant and equipment, net	224	315
Property, plant and equipment net, including construction in progress	46,445	44,874
Leasehold improvements [Member]
Property, plant and equipment, gross	69	69
Office furniture and equipment [Member]
Property, plant and equipment, gross	25	25
Computer equipment and software [Member]
Property, plant and equipment, gross	635	626
Construction in progress (property in the United Kingdom) [Member]
Total property, plant and equipment, net	$ 46,221	$ 44,559

Property & Equipment and Cons38

Property & Equipment and Construction in Progress (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Depreciation	$ 100,000	$ 80,000

Stock-based Compensation (Detai

Stock-based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Number of Options, Outstanding	1,551
Number of Options, Granted	11,343
Number of Options, Forfeited/expired	(238)
Number of Options, Outstanding	12,656	1,551
Number of Options, Options vested and exercisable	6,546
Weighted Average Exercise Price, Outstanding	$ 10.56
Weighted Average Exercise Price, Granted	0.25
Weighted Average Exercise Price, Forfeited/expired	9.90
Weighted Average Exercise Price, Outstanding	1.32	$ 10.56
Weighted Average Exercise Price, Options vested and exercisable	$ 1.63
Total Intrinsic Value, Outstanding	$ 0	$ 0
Total Intrinsic Value, Options vested and exercisable	$ 0
Weighted Average Remaining Contractual Life (in years), Outstanding	4 years 7 months 6 days	1 year 10 months 24 days
Weighted Average Remaining Contractual Life (in years), Granted	5 years
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable	4 years 6 months

Stock-based Compensation (Det40

Stock-based Compensation (Details 1)	6 Months Ended
	Jun. 30, 2017$ / shares
Exercise price	$ 0.25
Expected term (years)	2 years 9 months 18 days
Expected stock price volatility	96.00%
Risk-free rate of interest	2.00%

Stock-based Compensation (Det41

Stock-based Compensation (Details Textual) - USD ($)	Jun. 13, 2017	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.25
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	50% will vest over a 24-month period in equal monthly installments, provided that the recipient continues to be employed by the Company. The unvested portions of the Options are subject to accelerated vesting upon (i) a change of effective control of the Company, (ii) the filing of the first Biologics License Application or other application for product approval in any jurisdiction, (iii) completion of any randomized clinical trial that meets its endpoint(s) (Phase II or Phase III), (iv) decision by the Board, in its discretion or (v) the death of the recipient.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 700,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 300,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 2 months 12 days
Research and Development Expense [Member]
Allocated Share-based Compensation Expense		$ 373,000
Chief Technical Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	7,940,182
Chief Scientific Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	3,402,935

Outstanding Debt (Details)

Outstanding Debt (Details) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended		12 Months Ended
		Jun. 30, 2017		Dec. 31, 2016
Face Amount		$ 32,664		$ 32,561
Remaining Debt Discount		(3,063)		(850)
Debt Premium		348
Convertible Notes, Net (Includes Related Party Of 0 and 3,588 In 2012 and 2011, Respectively)		3,495		10,960
Notes Payable, Related Parties, Current		2,170		310
Short-term Debt, Fair Value		4,749		5,200
Secured Debt, Current		6,115		9,791
Convertible Notes Payable, Noncurrent		5,383		0
Secured Long-term Debt, Noncurrent		4,453		0
Long-term Debt		32,026		31,711
Fair Value of Embedded Conversion Option		2,077
Notes Payable, Current		5,661		2,450
Short-term Debt [Member]
Face Amount		2,896		11,135
Remaining Debt Discount		0		(175)
Debt Premium		348
Convertible Notes, Net (Includes Related Party Of 0 and 3,588 In 2012 and 2011, Respectively)		3,495		10,960
Fair Value of Embedded Conversion Option		251
Short term notes payable [Member]
Face Amount		6,146		310
Remaining Debt Discount		(485)		0
Debt Premium		0
Notes Payable, Related Parties, Current				$ 310
Fair Value of Embedded Conversion Option		0
Notes Payable, Current		$ 5,661
Six Percent Unsecured [Member] | Short-term Debt [Member]
Maturity Date		Due	[1]	Due	[2]
Stated Interest Rate		6.00%	[1]	6.00%	[2]
Conversion Price		$ 3.09	[1]	$ 3.09	[2]
Face Amount		$ 135	[1]	$ 135	[2]
Remaining Debt Discount		0	[1]	0	[2]
Debt Premium	[1]	0
Convertible Notes, Net (Includes Related Party Of 0 and 3,588 In 2012 and 2011, Respectively)		135	[1]	$ 135	[2]
Fair Value of Embedded Conversion Option	[1]	$ 0
Ten Percent Unsecured [Member] | Short-term Debt [Member]
Maturity Date	[3]			Nov. 4, 2017
Maturity Date	[3]	In Default
Stated Interest Rate	[3]	10.00%		10.00%
Conversion Price	[3]	$ 0.26
Face Amount	[3]	$ 1,578		$ 2,450
Remaining Debt Discount	[3]	0		0
Debt Premium	[3]	0
Convertible Notes, Net (Includes Related Party Of 0 and 3,588 In 2012 and 2011, Respectively)	[3]	1,592
Fair Value of Embedded Conversion Option	[3]	$ 14
Notes Payable, Current	[3]			$ 2,450
Ten Percent Unsecured [Member] | Short term notes payable [Member]
Maturity Date		On Demand	[4]	On Demand
Stated Interest Rate		10.00%	[4]	10.00%
Conversion Price	[4]
Face Amount		$ 2,170	[4]	$ 50
Remaining Debt Discount		0	[4]	0
Debt Premium	[4]	0
Notes Payable, Related Parties, Current				$ 50
Fair Value of Embedded Conversion Option	[4]	0
Notes Payable, Current	[4]	$ 2,170
Eighteen Percent Unsecured [Member] | Short-term Debt [Member]
Maturity Date	[5]	In Default
Stated Interest Rate	[5]	18.00%
Conversion Price	[5]	$ 0.26
Face Amount	[5]	$ 1,183
Remaining Debt Discount	[5]	0
Debt Premium	[5]	348
Convertible Notes, Net (Includes Related Party Of 0 and 3,588 In 2012 and 2011, Respectively)	[5]	1,768
Fair Value of Embedded Conversion Option	[5]	$ 237
Eight Percent Unsecured [Member] | Short-term Debt [Member]
Maturity Date		Various
Stated Interest Rate	[6]	8.00%
Conversion Price	[6]
Face Amount	[6]	$ 5,620
Remaining Debt Discount	[6]	(400)
Debt Premium	[6]	0
Fair Value of Embedded Conversion Option	[6]	0
Notes Payable, Current	[6]	$ 5,220
Eight Percent Unsecured [Member] | Maximum [Member] | Short-term Debt [Member]
Maturity Date	[6]	Jun. 30, 2018
Eight Percent Unsecured [Member] | Minimum [Member] | Short-term Debt [Member]
Maturity Date	[6]	Sep. 3, 2017
Zero Percent Unsecured [Member] | Short-term Debt [Member]
Maturity Date	[7]	Sep. 1, 2017
Stated Interest Rate	[7]	0.00%
Conversion Price	[7]
Face Amount	[7]	$ 226
Remaining Debt Discount	[7]	(2)
Debt Premium	[7]	0
Fair Value of Embedded Conversion Option	[7]	0
Notes Payable, Current	[7]	$ 224
Twelve Percent Unsecured [Member] | Short-term Debt [Member]
Maturity Date	[7]	On Demand
Stated Interest Rate	[7]	12.00%
Conversion Price	[7]
Face Amount	[7]	$ 300
Remaining Debt Discount	[7]	(83)
Debt Premium	[7]	0
Fair Value of Embedded Conversion Option	[7]	0
Notes Payable, Current	[7]	$ 217
Twelve Percent Unsecured [Member] | Short term notes payable [Member]
Maturity Date				On Demand
Stated Interest Rate				12.00%
Face Amount				$ 260
Remaining Debt Discount				0
Notes Payable, Related Parties, Current				$ 260
Short term mortgage loan [Member] | Short-term Debt [Member]
Maturity Date		Nov. 16, 2017
Stated Interest Rate		12.00%		12.00%
Face Amount		$ 6,225		$ 10,156
Remaining Debt Discount		(110)		(365)
Debt Premium		0
Secured Debt, Current		6,115		$ 9,791
Fair Value of Embedded Conversion Option		0
Short term mortgage loan [Member] | Maximum [Member] | Short-term Debt [Member]
Maturity Date				Nov. 16, 2017
Short term mortgage loan [Member] | Minimum [Member] | Short-term Debt [Member]
Maturity Date				Aug. 13, 2017
Five Percent 2014 Senior convertible note [Member] | Short-term Debt [Member]
Maturity Date	[8]			Aug. 15, 2017
Stated Interest Rate	[8]			5.00%
Conversion Price	[8]			$ 6.60
Face Amount	[8]			$ 11,000
Remaining Debt Discount	[8]			(175)
Convertible Notes, Net (Includes Related Party Of 0 and 3,588 In 2012 and 2011, Respectively)	[8]			$ 10,825
Share Settled Debt [Member]
Long-term Debt		$ 4,700
Share Settled Debt [Member] | Short-term Debt [Member]
Maturity Date	[9]	In Default		In Default
Stated Interest Rate	[9]	18.00%		18.00%
Conversion Price	[9]	$ 0.16		$ 0.35
Face Amount	[9]	$ 4,749		$ 5,200
Remaining Debt Discount	[9]	0		0
Debt Premium	[9]	0
Short-term Debt, Fair Value	[9]	4,749		$ 5,200
Fair Value of Embedded Conversion Option	[9]	$ 0
Long term mortgage loan [Member] | Long-term Debt [Member]
Maturity Date	[10]	Aug. 13, 2018
Stated Interest Rate	[10]	12.00%
Conversion Price	[10]
Face Amount	[10]	$ 4,478
Remaining Debt Discount	[10]	(25)
Debt Premium	[10]	0
Secured Long-term Debt, Noncurrent	[10]	4,453
Fair Value of Embedded Conversion Option	[10]	$ 0
Twelve Percent Secured [Member] | Long-term Debt [Member]
Maturity Date	[8]	Jun. 21, 2020
Stated Interest Rate	[8]	12.00%
Conversion Price	[8]	$ 0.50
Face Amount	[8]	$ 6,000
Remaining Debt Discount	[8]	(2,443)
Debt Premium	[8]	0
Convertible Notes Payable, Noncurrent	[8]	5,383
Fair Value of Embedded Conversion Option	[8]	$ 1,826
Eight Percent unsecured note [Member] | Long-term Debt [Member]
Maturity Date	[6]			Jun. 30, 2018
Stated Interest Rate	[6]			8.00%
Conversion Price	[6]
Face Amount	[6]			$ 3,310
Remaining Debt Discount	[6]			(310)
Secured Debt, Current	[6]			$ 3,000
[1]	This $135,000 note as of June 30, 2017 and December 31, 2016 consists of two separate 6% notes in the amounts of $110,000 and $25,000. In regard to the $110,000 note due in 2011, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $25,000 note due in 2011, during the year ended December 31, 2013, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents.
[2]	This $135,000 note as of June 30, 2017 and December 31, 2016 consists of two separate 6% notes in the amounts of $110,000 and $25,000. In regard to the $110,000 note due in 2011, the Company has made ongoing attempts to locate the creditor to repay or convert this note, but has been unable to locate the creditor to date. In regard to the $25,000 note due in 2011, during the year ended December 31, 2013, the holder has elected to convert these notes into equity, the Company has delivered the applicable conversion documents to the holder, and the Company is waiting for the holder to execute and return the documents.
[3]	On November 4, 2016, the Company entered into three promissory notes agreement (“the Notes”) with an individual investor (“the Holder”) for an aggregate amount of $2.45 million. The Notes bore interest at the rate of 10% with 1 year term. On April 12, 2017, the Company entered a note amendment (“the Amendment”) with the Holder. The maturity date was amended to June 30, 2017, and the Holder was granted an option to convert outstanding principal amount and accrued interest into a package of (i) one share of common stock at conversion price of $0.26, (ii) 0.75 of a warrant with a strike price of $0.26 with a 5 years term, and (iii) 0.75 of a warrant with a strike price of $1.00 with a 3 months term. The Company recorded approximately $1.4 million debt extinguishment loss from this amendment. On May 22, 2017, the Company induced the holder to convert approximately $872,000 principal and $128,000 accrued interest of the Notes into 5,555,556 shares of common stock at fair value of $0.16, and 8,333,334 warrants at fair value of $0.11 using Black-Scholes model. The Company recorded approximately $349,000 debt extinguishment loss from this conversion.
[4]	Related Party Notes Goldman Notes During the quarter ended June 30, 2017, Leslie J. Goldman, an officer of the Company, loaned the Company an aggregate amount of $850,000 pursuant to multiple Demand Promissory Notes (the “Goldman Notes”). The Goldman Notes bear interest at 10% per annum, and are payable upon demand, with 7 days’ prior written notice by Mr. Goldman to the Company. During the quarter ended March 31, 2017, Leslie J. Goldman, an officer of the Company, loaned the Company $420,000 pursuant to two Demand Promissory Note Agreements (the “Goldman Notes”). The Goldman Notes bore interest at the rate of 12% per annum. During the six months ended June 30, 2017, the Company made an aggregate principal payment of $730,000 to settle all of Mr. Goldman’s outstanding demand notes, and an aggregate of $47,000 interest payment associated with these demand notes. Such payment included repayment of outstanding debt before 2017. Toucan Notes During the quarter ended June 30, 2017, Toucan Capital Fund III loaned the Company an aggregate amount of $1,170,000 pursuant to multiple Demand Promissory Notes (the “Toucan Notes”). The Toucan Notes bear interest at 10% per annum, and are payable upon demand, with 7 days’ prior written notice to the Company. In June 2017, the Company repaid $150,000 of the Toucan Notes. Board of Directors Notes During the quarter ended June 30, 2017, Jerry Jasinowski, Robert Farmer and Cofer Black, members of the Company’s Board of Directors, loaned the Company an aggregate amount of $300,000 pursuant to multiple Demand Promissory Notes (the “Notes”). The Notes bear interest at 10% per annum, and are payable upon demand, with 7 days’ prior written notice to the Company.
[5]	On March 3, 2017, the Company entered into a series of promissory notes (the “OID Notes”) with unrelated third parties (the “Holders”) in the original principal amount of $1,450,000 with an original issuance discount of 3% for aggregate net proceeds of $1.4 million with no stated interest rate. On April 10, 2017, the Company entered into multiple note amendments (“the Amendment”) with the OID Notes holders. The maturity date was amended to June 10, 2017, and the Holders were granted the option to convert outstanding principal amount and accrued interest into a package of (i) one share of common stock at the conversion price of $0.26, (ii) 0.75 of a warrant with a strike price of $0.26 with a 5 years term, and (iii) 0.75 of a warrant with a strike price of $1.00 with a 3 months term. The Company recorded approximately $1.0 million debt extinguishment loss from this amendment. On April 12, 2017, the Company made a repayment of $258,000 to one of the OID Notes holders. The Company accrued an additional $348,000 debt premium on the prepaid portion and any unpaid portion of the OID Notes after the maturity date pursuant to the default provision.
[6]	During six months ended June 30, 2017, the Company entered into two promissory notes agreement (the “Notes”) with the same investor for an aggregate principal amount of $2,310,000. The Notes bore interest at 8% per annum with a 6 month term. The Notes carries an original issue discount of $300,000 and $10,000 legal cost that was reimbursable to the investor. The remaining unamortized debt discount related the Notes was approximately $186,000 as of June 30, 2017. On December 30, 2016, the Company entered into a note purchase agreement (the “Note”) with an individual investor for an aggregate principal amount of $3,310,000. The Note bore interest at 8% per annum with 18 months term. The Note carries an original issue discount of $300,000 and $10,000 legal cost that was reimbursable to the investor. The remaining unamortized debt discount related the Note was approximately $214,000 as of June 30, 2017.
[7]	On June 29, 2017, the Company entered into a promissory note (the “Note”) agreement with an investor for the amount of $300,000. The Note bore interest at 12% per annum, and is payable upon demand. The Company also issued 833,333 warrants with a strike price of $0.18 in conjunction the note. The Company recorded $84,000 debt discount at the issuance date, which is the fair value of the warrants. On March 1, 2017, the Company entered into a promissory note (the “Note”) agreement with an investor in the original principal amount of $226,000 with an original issuance discount of 3% for net proceeds of $220,000 with no stated interest rate.
[8]	2014 Senior Convertible Notes Due to the Nasdaq delisting on December 19, 2016, the term of the 2014 Convertible Senior Notes (the “2014 Notes”) Indenture required the Company to offer to repurchase the entire principal and all remaining interest through the Notes’ original maturity date. The debt holders (the “Holders”) accepted the offer, and the Company was required to repurchase the entire 2014 Notes on March 10, 2017. The full repurchase of $11 million of 2014 Notes, as well as $660,000 of interest payments and cash and stock forbearance payments was completed during the six months ended June 30, 2017, through a series of transactions. During the six months ended June 30, 2017, the Company entered into multiple agreements to extend the date for payment of the 2014 Notes to June 20, 2017. As an additional consideration to the Holders to delay the 2014 Notes repayment, the Company issued the Holders an aggregate 7,089,860 common stock. The total forbearance charge of $2.6 million was recorded as a debt extinguishment loss and was based upon the fair value of the common stock of $2.1 million on the grant date and cash payments of $0.5 million. During the six months ended June 30, 2017, the Company repaid in cash $3.0 million of principal of the 2014 Notes, and repaid an additional $3.0 million of principal in common stock and warrants, and $5 million of principal of the 2014 Notes was repurchased by the investor pursuant to an Exchange Agreement and Note Agreement, as described below. 2017 Secured Convertible Notes On June 21, 2017, an unaffiliated institutional investor (the “Investor”) agreed to purchase $5.0 million of the 2014 Notes from the Holders, pursuant to a Purchase Agreement (the “Purchase Agreement”). Also on June 21, 2017, the Company and the Investor entered into an Exchange Agreement (the “Exchange Agreement”) pursuant to which the Investor agreed to exchange its $5.0 million of the 2014 Note for new convertible notes (the “2017 Notes”) with an aggregate principal amount of approximately $5.6 million, inclusive of original issue discount of approximately 9%. The Company and the Investor also entered another secured convertible note with an aggregate principal amount of approximately $350,000, inclusive of original issue discount of approximately 9%, for $325,000 in cash. Total debt outstanding as of June 30, 2017 was $6.0 million under the 2017 Secured Convertible Notes. The 2017 Notes have a 3-year maturity and bear interest at 12% per annum. No interest will be payable during the term, but interest will accrue and be payable at maturity. The 2017 Notes are secured by the property owned by the Company in the U.K., and not by any other assets of the Company. The 2017 Notes and accrued interest will be convertible at any time during the term at fixed conversion prices: 50% of the principal and accrued interest will be convertible at $0.25 per share, 25% of the principal and accrued interest will be convertible at $0.50 per share and 25% of the principal and accrued interest will be convertible at $1.00 per share. The transaction was accounted for as a debt extinguishment. The Company recorded an approximate $1.8 million embedded conversion feature on the 2017 Notes as part of debt discount on the issuance date. The was no change in fair value from these embedded conversion features from June 21, 2017 to June 30, 2017.
[9]	During the six months ended June 30, 2016, the holder of the Company’s share-settled debt converted approximately $0.5 million of outstanding share-settled debt.
[10]	The mortgage loan, which was originally due in August 2017 has been auto renewed for additional one year until August 17, 2018.

Outstanding Debt (Details 1)

Outstanding Debt (Details 1) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Other interest expenses	$ 3	$ 0	$ 5	$ 1
Additional debt premium	348		348
Amortization of debt discount			687	431
Interest Expense, Debt	1,308	729	2,502	1,447
Secured Debt [Member]
Contractual interest	360	332	649	665
Amortization of debt issuance costs	123	152	242	291
Interest Expense, Debt	483	484	891	956
Notes Payable, Other Payables [Member]
Contractual interest	245	38	389	76
Additional debt premium	348	0	348	0
Amortization of debt discount	190	0	270	0
Interest Expense, Debt	783	38	1,007	76
Senior Convertiable Note [Member]
Contractual interest	39	137	424	274
Amortization of debt issuance costs	0	70	175	140
Interest and Debt Expense	$ 39	$ 207	$ 599	$ 414

Outstanding Debt (Details Textu

Outstanding Debt (Details Textual) - USD ($)	Jun. 14, 2017	Apr. 12, 2017	Apr. 10, 2017	Mar. 03, 2017	Mar. 01, 2017	Nov. 04, 2016	Jun. 29, 2017	Jun. 21, 2017	Jun. 05, 2017	May 22, 2017	Mar. 30, 2017	Dec. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2013
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Amount									$ 500,000	$ 2,000,000					$ 451,000	$ 0
Debt Conversion, Converted Instrument, Shares Issued									3,300,000	11,137,345
Debt Instrument, Face Amount													$ 32,664,000		32,664,000			$ 32,561,000
Debt Instrument, Unamortized Discount													$ 3,063,000		$ 3,063,000			850,000
Class of Warrant or Right, Exercise Price of Warrants or Rights													$ 0.33		$ 0.33
Notes Payable													$ 135,000		$ 135,000			135,000
Legal Fees													2,003,000	$ 4,541,000	5,935,000	5,481,000
Proceeds from Notes Payable															3,973,000	0
Gain (Loss) on Extinguishment of Debt									$ (400,000)	$ (700,000)			(7,007,000)	$ 0	(8,542,000)	0
Embedded Derivative, Fair Value of Embedded Derivative Liability													$ 2,075,000		$ 2,075,000
Debt Instrument, Increase, Accrued Interest										$ 128,000
Note One [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							12.00%						8.00%		8.00%
Debt Instrument, Face Amount							$ 300,000
Debt Instrument, Unamortized Discount													$ 186,000		$ 186,000
Debt Instrument, Term															6 months
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right							833,333
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.18
Debt Related Commitment Fees and Debt Issuance Costs							$ 84,000								$ 300,000
Legal Fees															10,000
Debt Instrument, Periodic Payment, Principal															2,310,000
Note Two [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					3.00%							8.00%
Debt Instrument, Face Amount					$ 226,000
Debt Instrument, Unamortized Discount												$ 214,000
Debt Instrument, Term												18 months
Debt Related Commitment Fees and Debt Issuance Costs												$ 300,000
Legal Fees												10,000
Debt Instrument, Periodic Payment, Principal												$ 3,310,000
Proceeds from Notes Payable					$ 220,000
Promissory Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage						10.00%
Debt Instrument, Face Amount						$ 2,450,000
Debt Instrument, Term						1 year
Note Due In 2011 [Member]
Debt Instrument [Line Items]
Notes Payable													$ 110,000		$ 110,000				$ 25,000
Goldman Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage													10.00%		10.00%		12.00%
Debt Instrument, Face Amount													$ 850,000		$ 850,000		$ 420,000
Debt Instrument, Term													7 days
Debt Instrument, Periodic Payment, Principal															730,000
Debt Instrument, Periodic Payment, Interest															47,000
Six Percentage Note Payable One [Member]
Debt Instrument [Line Items]
Notes Payable													$ 110,000		$ 110,000
Six Percentage Note Payable Two [Member]
Debt Instrument [Line Items]
Notes Payable																		$ 25,000
Share Settled Debt [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	1,000,000										2,500,000				3,500,000
Debt Instrument, Periodic Payment, Principal																$ 500,000
ODI Notes Holders [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				3.00%
Debt Instrument, Face Amount				$ 1,450,000
Debt Instrument, Unamortized Discount													348,000		$ 348,000
Repayments of Notes Payable		$ 258,000
Proceeds from Notes Payable				$ 1,400,000
Gain (Loss) on Extinguishment of Debt			$ 1,000,000
Embedded Derivative, Fair Value of Embedded Derivative Liability													237,000		237,000
Debt Instrument, Description			(i) one share of common stock at the conversion price of $0.26, (ii) 0.75 of a warrant with a strike price of $0.26 with a 5 years term, and (iii) 0.75 of a warrant with a strike price of $1.00 with a 3 months term.
Note Amendment [Member]
Debt Instrument [Line Items]
Gain (Loss) on Extinguishment of Debt		$ 1,400,000
Embedded Derivative, Fair Value of Embedded Derivative Liability													14,000		$ 14,000
Debt Instrument, Description															(i) one share of common stock at conversion price of $0.26, (ii) 0.75 of a warrant with a strike price of $0.26 with a 5 years term, and (iii) 0.75 of a warrant with a strike price of $1.00 with a 3 months term.
Senior Convertible Notes 2014 [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued															7,089,860
Repayments of Other Long-term Debt															$ 3,000,000
Debt Instrument, Face Amount													500,000		500,000
Repayments Of Convertible Notes Payable															11,000,000
Fair Value Of Common Stock															2,100,000
Debt Instrument, Periodic Payment, Principal															5,000,000
Debt Instrument, Periodic Payment, Interest															660,000
Gain (Loss) on Extinguishment of Debt															2,600,000
Senior Convertible Notes 2017 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								12.00%
Embedded Derivative, Fair Value of Embedded Derivative, Net													$ 1,800,000		$ 1,800,000
Debt Instrument, Term								3 years
Debt Instrument, Periodic Payment, Principal								$ 6,000,000
Debt Instrument, Description															The 2017 Notes and accrued interest will be convertible at any time during the term at fixed conversion prices: 50% of the principal and accrued interest will be convertible at $0.25 per share, 25% of the principal and accrued interest will be convertible at $0.50 per share and 25% of the principal and accrued interest will be convertible at $1.00 per share.
Investor [Member] | Senior Convertible Notes 2017 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								9.00%
Debt Instrument, Face Amount								$ 5,000,000
Debt Instrument, Periodic Payment, Principal								$ 5,600,000
Toucan Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage													10.00%		10.00%
Debt Instrument, Face Amount													$ 1,170,000		$ 1,170,000
Debt Instrument, Term													7 days
Repayments of Notes Payable													$ 150,000
Board of Directors Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage													10.00%		10.00%
Debt Instrument, Face Amount													$ 300,000		$ 300,000
Debt Instrument, Term													7 days
Investor Another Secured Notes [Member] | Senior Convertible Notes 2017 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								9.00%
Repayments Of Convertible Notes Payable								$ 325,000
Debt Instrument, Periodic Payment, Principal								$ 350,000
Common Stock [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued										5,555,556
Debt Instrument, Convertible, Conversion Price										$ 0.16
Warrant [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued										8,333,334
Debt Instrument, Convertible, Conversion Price										$ 0.11
Class of Warrant or Right, Exercise Price of Warrants or Rights													$ 0.01		$ 0.01
Common Stock and Warrants [Member] | Senior Convertible Notes 2014 [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal															$ 3,000,000

Net Loss per Share Applicable45

Net Loss per Share Applicable to Common Stockholders (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	192,778	47,760
Common stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	12,656	1,551
Common stock warrants equity treatment [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	37,554	23,276
Common stock warrants liability treatment [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	84,135	21,169
Convertible notes and accrued interest [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	27,501	1,764
Share Settled Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	30,932	0

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Cognate research and development cost - services	$ 5,466,000	$ 8,713,000	$ 10,501,000	$ 22,153,000
Debt Instrument, Face Amount	32,664,000		32,664,000			$ 32,561,000
Trade Liabilities Waived by Related Parties, Amount	3,750,000		3,750,000
Goldman Note [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	$ 850,000		$ 850,000		$ 420,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%		10.00%		12.00%
Debt Instrument, Periodic Payment, Principal			$ 730,000
Debt Instrument, Periodic Payment, Interest			47,000
Cognate Bioservices [Member]
Related Party Transaction [Line Items]
Cognate research and development cost - services	$ 2,600,000	$ 5,500,000	5,200,000	$ 16,600,000
Accounts Payable, Related Parties	21,400,000		21,400,000			23,400,000
Cognate [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties						$ 3,750,000
Related Party Transaction, Expenses from Transactions with Related Party	1,500,000		2,300,000
Toucan Notes [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	$ 1,170,000		$ 1,170,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%		10.00%
Repayments of Debt			$ 150,000
Various Related Parties [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	$ 300,000		$ 300,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%		10.00%

Stockholders' Equity (Deficit47

Stockholders' Equity (Deficit) (Details) - $ / shares shares in Thousands		6 Months Ended	12 Months Ended
		Jun. 30, 2017	Dec. 31, 2016
Shareholders Deficit [Line Items]
Number of Warrants, Outstanding		58,278
Number of Warrants, Warrants granted	[1]	96,530
Number of Warrants, Warrants exercised for cash		(10,800)
Number of Warrants, Warrants expired and cancellation		(22,319)
Number of Warrants, Outstanding		121,689	58,278
Weighted Average Exercise Price - Outstanding		$ 1.78
Weighted Average Exercise Price - Warrants granted	[1]	0.48
Weighted Average Exercise Price - Warrants exercised for cash		0.02
Weighted Average Exercise Price - Warrants expired and cancelled		1.24
Weighted Average Exercise Price - Outstanding		$ 0.98	$ 1.78
Remaining Contractual Term		3 years 1 month 6 days	3 years 10 months 10 days
[1]	Including approximately 1.0 million ratchet warrants due to the exercise price reset during the six months ended June 30, 2017.

Stockholders' Equity (Deficit48

Stockholders' Equity (Deficit) (Details Textual) - USD ($)	Jun. 14, 2017	Apr. 14, 2017	Mar. 10, 2017	Jul. 17, 2017	Jun. 05, 2017	May 31, 2017	May 22, 2017	Mar. 31, 2017	Mar. 30, 2017	Mar. 17, 2017	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Oct. 17, 2017	Dec. 31, 2016
Shareholders Deficit [Line Items]
Shares Issued, Price Per Share		$ 0.26			$ 0.14		$ 0.18				$ 0.15			$ 0.15
Proceeds from Warrant Exercises												$ 31,000		$ 100,000	$ 4,235,000
Debt Conversion, Converted Instrument, Amount					$ 500,000		$ 2,000,000							$ 451,000	0
Stock Issued During Period, Shares, New Issues		1,384,615								18,800,000	3,610,452
Debt Conversion, Converted Instrument, Shares Issued					3,300,000		11,137,345
Proceeds from Issuance of Common Stock		$ 360,000									$ 552,000
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 0.33			$ 0.33
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										0.01	3,274,553			3,274,553
Proceeds from Issuance or Sale of Equity										$ 7,500,000
Warrants Not Settleable in Cash, Fair Value Disclosure								$ 713,000				$ 713,000
Gain (Loss) on Extinguishment of Debt					$ (400,000)		$ (700,000)				$ (7,007,000)		$ 0	$ (8,542,000)	$ 0
Shares Issued During Period Shares, Upon Exercise Of warrants												3,100,000
Warrants and Rights Outstanding					300,000	$ 1,600,000	900,000
Debt Instrument, Face Amount											32,664,000			32,664,000			$ 32,561,000
Common Stock, Value, Outstanding					$ 600,000	3,900,000	$ 1,800,000
Long-term Debt											$ 32,026,000			$ 32,026,000			$ 31,711,000
Class Of Warrants Or Rights Number Of Ratchet Warrants											1,000,000			1,000,000
Senior Convertiable Note [Member]
Shareholders Deficit [Line Items]
Debt Conversion, Converted Instrument, Amount			$ 1,500,000
Debt Conversion, Converted Instrument, Shares Issued			4,039,860								3,050,000
Debt Instrument, Face Amount			$ 11,000,000								$ 11,000,000			$ 11,000,000
Share Settled Debt [Member]
Shareholders Deficit [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	1,000,000								2,500,000					3,500,000
Long-term Debt											4,700,000			$ 4,700,000
2014 Senior Convertible Notes [Member]
Shareholders Deficit [Line Items]
Debt Conversion, Converted Instrument, Amount						$ 3,000,000
Debt Conversion, Converted Instrument, Shares Issued						20,628,571
Gain (Loss) on Extinguishment of Debt											(500,000)
Series A Warrants [Member]
Shareholders Deficit [Line Items]
Sale of Stock, Price Per Share										$ 0.26
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.26
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										21,600,000
Class of Warrants, Expiration Term										5 years
Series B Warrants [Member]
Shareholders Deficit [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										21,600,000
Series C Warrants [Member]
Shareholders Deficit [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.26		$ 0.26		$ 0.26
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										10,000,000
Class Of Warrant Or Right Prefunded Exercise Price								$ 0.25		$ 0.25		$ 0.25
Warrants and Rights Outstanding								$ 6,200,000				$ 6,200,000
Class A Warrant [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Shares, New Issues				6,939,934
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.26					$ 0.26
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,038,461		16,071,428			8,353,009
Class of Warrants, Expiration Term		5 years					5 years
Class B Warrant [Member]
Shareholders Deficit [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1					$ 1									$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,038,461		1,038,460			8,353,009
Class of Warrants, Expiration Term		3 months					90 days	90 years
Class D Warrant [Member]
Shareholders Deficit [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.175
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					2,475,000
Class of Warrant or Right, Warrant Term					2 years
Warrant [Member]
Shareholders Deficit [Line Items]
Proceeds from Warrant Exercises											$ 69,000
Stock Issued During Period, Shares, New Issues														6,900,000
Debt Conversion, Converted Instrument, Shares Issued							8,333,334
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 0.01			$ 0.01
Warrants and Rights Outstanding											$ 1,100,000			$ 1,100,000
Warrant [Member] | 2014 Senior Convertible Notes [Member]
Shareholders Deficit [Line Items]
Stock Issued During Period, Shares, New Issues						800,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.175
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						16,071,428
Class of Warrant or Right, Warrant Term						2 years

Variable Interest Entities (Det

Variable Interest Entities (Details Textual) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Millions	Jun. 30, 2017	Oct. 31, 2016
Variable Interest Entity [Line Items]
Variable Interest Entity, Consolidated, Carrying Amount, Liabilities		$ 5.7
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount	$ 4.5

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	Aug. 14, 2017	Jun. 22, 2017	Jan. 17, 2014
Commitments And Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 446,000
Loss Contingency, Damages Sought		The complaint asserts claims for breach of contract and unjust enrichment, and purports to seek at least $1 million, interest, and attorneys fees and costs.
DCVax-Direct Agreement [Member] | Condition One [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount			$ 3,000,000
DCVax-Direct Agreement [Member] | Condition Two [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount			5,000,000
DCVax-Direct Agreement [Member] | Condition Three [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount			1,500,000
DCVax-Direct Agreement [Member] | Condition Four [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount			2,000,000
DCVax-Direct Agreement [Member] | Condition Five [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount			3,000,000
DCVax-Direct Agreement [Member] | Condition Six [Member]
Commitments And Contingencies [Line Items]
Contingent Liability Dcvax Direct Agreement Amount			$ 5,000,000

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	Aug. 07, 2017	Aug. 04, 2017	Aug. 01, 2017	Jul. 11, 2017	Jul. 10, 2017	Jul. 06, 2017	Jun. 14, 2017	Apr. 14, 2017	Jul. 17, 2017	Jun. 05, 2017	May 22, 2017	Mar. 31, 2017	Mar. 30, 2017	Mar. 17, 2017	Aug. 31, 2017	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Oct. 17, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Shares Issued, Price Per Share								$ 0.26		$ 0.14	$ 0.18					$ 0.15	$ 0.15
Stock Issued During Period, Shares, New Issues								1,384,615						18,800,000		3,610,452
Common Stock, Par Or Stated Value Per Share																$ 0.001	0.001			$ 0.001
Debt Conversion, Converted Instrument, Shares Issued										3,300,000	11,137,345
Class of Warrant or Right, Exercise Price of Warrants or Rights																$ 0.33	$ 0.33
Debt Conversion, Converted Instrument, Amount										$ 500,000	$ 2,000,000						$ 451,000	$ 0
Proceeds from Issuance or Sale of Equity														$ 7,500,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights														0.01		3,274,553	3,274,553
Class A Warrant [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues									6,939,934
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.26			$ 0.26
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								1,038,461	16,071,428		8,353,009
Class of Warrants, Expiration Term								5 years			5 years
Class B Warrant [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 1			$ 1								$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								1,038,461	1,038,460		8,353,009
Class of Warrants, Expiration Term								3 months			90 days	90 years
Class D Warrant [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.175
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										2,475,000
Share Settled Debt [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Shares Issued							1,000,000						2,500,000				3,500,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Shares Issued, Price Per Share		$ 0.20	$ 0.18		$ 0.12	$ 0.16			$ 0.16
Stock Issued During Period, Shares, New Issues			5,000,000	200,000		1,312,500
Sale of Stock, Price Per Share			$ 0.20	$ 0.16
Stock Issued During Period, Value, New Issues			$ 1,000,000	$ 32,000
Debt Conversion, Converted Instrument, Shares Issued		5,000,000	9,059,107		3,335,730				10,086,853
Debt Conversion, Converted Instrument, Amount		$ 1,000,000	$ 1,200,000		$ 412,000				$ 1,600,000
Proceeds from Issuance of Debt															$ 900,000
Proceeds from Issuance or Sale of Equity															$ 4,600,000
Debt Conversion Converted Instrument Accrued Interest Amount			39,000						$ 36,000
Debt Conversion Converted Instrument Premium Amount			$ 407,000
Subsequent Event [Member] | Class A Warrant [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	13,527,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.27	$ 0.23	$ 0.18						$ 0.18
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,442,890	13,588,663						7,565,139
Class of Warrants, Expiration Term	5 years	2 years	5 years						5 years
Subsequent Event [Member] | Class B Warrant [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	2,700,000
Common Stock, Par Or Stated Value Per Share	$ 13,527,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.30	$ 1						$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,442,890	6,794,333						7,565,139
Class of Warrants, Expiration Term		2 years	90 days						90 days
Subsequent Event [Member] | Class D Warrant [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.23	$ 0.175
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			2,500,000	150,000
Class of Warrants, Expiration Term				2 years
Subsequent Event [Member] | Minimum [Member] | Class B Warrant [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.20
Subsequent Event [Member] | Maximum [Member] | Class B Warrant [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1
Unaffiliated Investor [Member] | Subsequent Event [Member] | Class D Warrant [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.30